1/15
08:25 am
sxtp
60 Degrees Pharma announces 1-for-4 reverse stock split; shares up [Seeking Alpha]
Medium
Report
60 Degrees Pharma announces 1-for-4 reverse stock split; shares up [Seeking Alpha]
1/15
08:01 am
sxtp
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
High
Report
60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio
12/30
04:09 pm
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/29
08:48 am
sxtp
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State [Yahoo! Finance]
High
Report
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State [Yahoo! Finance]
12/29
08:01 am
sxtp
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
High
Report
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
12/23
04:09 pm
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
08:27 am
sxtp
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 [Yahoo! Finance]
High
Report
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 [Yahoo! Finance]
12/11
08:01 am
sxtp
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
High
Report
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
11/28
08:00 am
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target lowered by analysts at Ascendiant Capital Markets from $3.00 to $2.80. They now have a "buy" rating on the stock.
Low
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its price target lowered by analysts at Ascendiant Capital Markets from $3.00 to $2.80. They now have a "buy" rating on the stock.
11/21
08:01 am
sxtp
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
Low
Report
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
11/20
06:03 am
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by analysts at Zacks Research to a "hold" rating.
Neutral
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) was upgraded by analysts at Zacks Research to a "hold" rating.
11/14
08:09 am
sxtp
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
High
Report
60 Degrees Pharmaceuticals (NASDAQ:SXTP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
11/13
02:09 pm
sxtp
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results [Yahoo! Finance]
Low
Report
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results [Yahoo! Finance]
11/13
01:51 pm
sxtp
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results
Low
Report
60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results